Earnings Insights

AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.

How to use these insights

Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.

Interarch Building Solutions Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

Post-FY26, growth could accelerate further to 20-25% annually due to increased capacity utilization and operating leverage. Key concall takeaways from…

6 Aug 2026

VVIP Infratech Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

They plan to focus on larger tenders in the ₹300-500 crore range to leverage their technical expertise. Key concall takeaways from VVIP Infratech Ltd's Q1 FY26…

6 Aug 2026

Sahaj Solar Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

Upcoming capacity expansions, including the first 750 additional capacity and new manufacturing lines (e.g., TOPCon panels with >21% efficiency), will enable…

6 Aug 2026

S A Tech Software India Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

100 crores to Rs. Key concall takeaways from S A Tech Software India Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

6 Aug 2026

Brainbees Solutions Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

India multi-channel business shows growth with orders up by 8% in Q2 FY26 compared to the same quarter last year. Key concall takeaways from Brainbees…

6 Aug 2026

Ceigall India Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Ceigall plans to leverage a strong order book (~INR13,295 crores) with multi-year revenue visibility. Key concall takeaways from Ceigall India Ltd's Q3 FY26…

6 Aug 2026

Akums Drugs & Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

300 crores linked to European markets. Key concall takeaways from Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

6 Aug 2026

Akums Drugs & Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

API Business:** Planning ~10% volume growth but revenues and profits dependent on Cephalosporin prices. Key concall takeaways from Akums Drugs &…

6 Aug 2026

Akums Drugs & Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

12%-13% revenue growth. Key concall takeaways from Akums Drugs & Pharmaceuticals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

6 Aug 2026

Ola Electric Mobility Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

. Key concall takeaways from Ola Electric Mobility Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

6 Aug 2026

Bansal Wire Industries Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Revenue growth complemented by product mix changes and backward integration, with capex of about INR 700-750 crores planned over FY '26 and FY '27 primarily…

6 Aug 2026

Bansal Wire Industries Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

Historically, the company has achieved 20%-25% volume growth, outpacing the industry growth of 6%-7%. Key concall takeaways from Bansal Wire Industries Ltd's…

6 Aug 2026

Emcure Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

International markets showed strong momentum, growing 22% YoY, with emerging markets growing 42%. Key concall takeaways from Emcure Pharmaceuticals Ltd's Q1…

6 Aug 2026

Emcure Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

R&D spend is maintained at 4%-5% to support innovation and biologics. Key concall takeaways from Emcure Pharmaceuticals's Q3 FY25 earnings call — and how it…

6 Aug 2026

Hoac Foods India Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

ft.) will increase capacity, potentially generating around INR 100 crores turnover at full capacity (Page 7). Key concall takeaways from Hoac Foods India Ltd's…

6 Aug 2026

GSM Foils Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Focus on increasing volumes with existing clients (50-60% capacity currently utilized); new client addition contributing 10-15% of growth mainly in Ahmedabad…

6 Aug 2026

GSM Foils Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

250 crores, reflecting an 80%-90% growth over previous years. Key concall takeaways from GSM Foils Ltd's Q2 FY26 earnings call — and how it ranks against…

6 Aug 2026

GSM Foils Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

Monthly sales have recently been around INR 16 to 17 crores. Key concall takeaways from GSM Foils Ltd's Q4 FY25 earnings call — and how it ranks against sector…

6 Aug 2026

Indian Emulsifiers Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

PAT margins to be maintained at similar levels to EBITDA margins, around 19%-22% (Page 24). Key concall takeaways from Indian Emulsifiers Ltd's Q2 FY26…

6 Aug 2026

Indian Emulsifiers Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

Focus on niche and higher-margin products alongside expansion in direct sales (currently 50-60% direct sales). Key concall takeaways from Indian Emulsifiers…

6 Aug 2026

Arthneeti Pro · Annual

Every earnings call this season,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access